

Notification of Changes to Service Provision

**3/4/2018**

Clinical Biochemistry

York Teaching Hospital NHS Foundation Trust

**Introduction**

In August 2017, following a competitive tender that was awarded to Roche Diagnostics, Laboratory Medicine undertook the first phase of a major laboratory equipment upgrade, replacing the immunoassay analysers simultaneously in the Clinical Biochemistry labs at York and Scarborough. We are now in a position to implement our new core chemistry analysers on 3rd April 2018, which will involve minor changes in results for some of our core assays (See next page).

**Only information regarding expected significant changes that may impact on patient management has been included in this notification. Where changes have occurred we will alert you to these using automated comments that will appear on reports.**

If you have any queries regarding the content of this notification then please do not hesitate to contact the laboratory using the contact details provided below.

Maria de Ferrars

Senior Clinical Scientist

01904 725599

maria.de.Ferrars@york.nhs.uk

Dr Daniel Turnock

Consultant Clinical Biochemist

01904 721847

daniel.turnock@york.nhs.uk

Ms Alison Jones

Consultant Clinical Biochemist and Lead Clinician for Chemical Pathology

01904 725786

alison.jones@york.nhs.uk

Duty Biochemist

01904 726366

**Summary of major changes**

|  |  |
| --- | --- |
| **ALT** | Approximately 10% decrease in results on the new method |
| **ALP** | Approximately 10% decrease in results on the new method |
| **Bilirubin** | Approximately 10% decrease in results on the new method |
| **CRP** | Approximately 10% decrease in results on the new method |
| **Bicarbonate** | Approximately 20% decrease in results on the new method |
| **Urine Protein** | Approximately 20% decrease in results on the new method |
| **Digoxin** | Approximately 20% decrease in results on the new method |
| **Adj Calcium** | Approximate 0.05 to 0.1 mmol/L decrease on new method\* |

\*There may be a slight increase in the incidence of borderline low calcium (2.1-2.2 mmol/L)

**Other changes (Scarborough, Bridlington and Whitby sites)**

|  |  |
| --- | --- |
| **Sodium** | Result may be 2 mmol/L higher on new method |

**Other changes (All sites)**

|  |  |
| --- | --- |
| **Test** | **Details of Change** |
| AST | Approximately 20% decrease in results on the new method |
| Valproate | Approximately 15% decrease in results on the new method |
| Theophyline | Approximately 20% increase in results on the new method |
| ACE | Approximately 25% decrease in results on the new method |
| C4 | Approximately 10% decrease in results on the new method |
| Ammonia | Approximately 15% decrease in results on the new method |
| Direct Bilirubin | Approximately 20% decrease in results on the new method |

**There will be no change to reference ranges for the above tests**

There will be minor changes to the following reference ranges:

|  |  |  |
| --- | --- | --- |
| **Test** | **New reference range** | **Previous reference range** |
| Creatinine | Male: 59-104 umol/LFemale: 45-84 umol/LAge specific in children | Male: 64-104 umol/LFemale: 49-90umol/LAge specific in children |
| Iron | 5.83 – 34.5 umol/L | Male: 12.5-32.2 umol/LFemale: 10.7-32.2umol/L |
| LDH | Males: 135 – 225 U/LFemales 135 – 214 U/LAge specific in children | <248 U/L |
| Beta-2 Microglobulin | 0.8 – 2.2 mg/L | 0.8 – 2.4 mg/L |